Uniphar PLC · EURONEXT:UPR
Uniphar — FY2020 Earnings Presentation
39 slides from Uniphar's earnings presentation, Mar 2, 2021

Slide 1: Delivering Growth - 2020 Preliminary Results Presentation
Delivering Growth Serving over 160 Countries worldwide 2020 Preliminary Results Presentation 2 March 2021

Slide 2: Important Notice
Important Notice This presentation has been prepared solely in connection with the financial results of Uniphar plc (the "Company") for the year ended 31 December 2020 and should be read in conjunction with the announcement of the Preliminary results of the Company for the year ended 31 December 202

Slide 3: Agenda
Agenda 1. Overview & Highlights 4. Strategic Initiatives 2. Divisional Review 5. Outlook & Investment Case > Commercial & Clinical 6. Q&A > Product Access > Supply Chain & Retail 3. Financial Review Presenters Ger Rabbette Tim Dolphin Padraic Dempsey Chief Executive Officer Chief Financial Officer C

Slide 4: Uniphar at a Glance
Uniphar at a Glance Divisional Gross Profit A diversified international healthcare service Strong performance across Commercial & Clinical and Product provider Access Supporting 200 multinational pharmaceutical Organic 200 and medical manufacturers across three divisions 2020 Growth Growth €’m % % 2

Slide 5: Highlights – FY20
Highlights – FY20 Strong performance with strategic initiatives progressed > Critical role throughout pandemic > Financial outperformance • EBITDA1 €66.7m (2019: €58.6m) • Adj EPS: 12.6 cent (up 26% LFL2) • ROCE3 18.9% (2019: 17.3%) > M&A Execution & Integration • 4 strategic acquisitions completed

Slide 6: Co-ordinated response to COVID-19
Co-ordinated response to COVID-19 Ensuring continuation of vital services: > Supporting front line staff > Leveraging our digital solutions > Ensuring uninterrupted supply of critical medicine, medical devices and related services > Consultation and strategic planning discussions with Government & R

Slide 7: 2020 Sustainability Highlights
2020 Sustainability Highlights Sustainable Development Goals We fully endorse the UN Sustainable Development Goals and consider the following goals to be most relevant to Uniphar and our Integrity – Inclusivity – Legacy – Stewardship - Transparency stakeholders: People & Workplace > Wellbeing of sta

Slide 8: Divisional Review
Divisional Review uniphar.ie 8

Slide 9: Commercial & Clinical
Commercial Building a pan-European service offering from & Clinical our present footprint in Ireland, the UK, Benelux Sales, marketing and distribution the Nordics & the US solutions for manufacturers Gross Profit Revenue Gross Profit Financials €269.8m €92.2m FY 2019 Reported FY 2020 Reported Gross

Slide 10: Product Access
Product Access Platform in place to become a global leader in Providing access to unlicensed and the provision of On Demand and Exclusive speciality medicines globally Access services Gross Profit Revenue Gross Profit Financials €187.5m €30.4m 2019 Reported 2019 Pro Forma (Incl Durbin) Gross Profit

Slide 11: Supply Chain & Retail
Supply Chain & Retail Leverage high-tech distribution facilities, Market leader in Irish wholesale and hospital market. longstanding manufacturer relationships and Supported by a network of 346 pharmacies.(1) scalable digital infrastructure Uniphar Volume Growth vs Market Volume Growth Revenue Gross

Slide 12: Financial Review
Financial Review uniphar.ie 12

Slide 13: Financial Highlights
Financial Highlights > Gross profit growth % Growth across all three divisions Constant (€m) 2020 2019 Reported currency 1 Organic 2 > 20.3% Reported Growth Revenue 1,823.9 1,665.3 9.5% 9.7% 4.5% > Strong overall EBITDA Gross profit 217.3 180.6 20.3% 20.6% 6.7% growth Gross profit margin 11.9% 10.8%

Slide 14: Divisional Gross Profit and Composition
Divisional Gross Profit Divisional Composition Diversified healthcare services business focused on higher margin opportunities 44% Organic 2020 2019 Growth Growth 2020 €’m €’m % % €217.3m GP Commercial & Clinical 92.2 76.8 20.1% 9.6% 14% 42% Product Access 30.4 17.2 76.9% 28.9% Supply Chain & Retail

Slide 15: Net Bank Debt Analysis
Net Bank Debt1 Analysis €34.4m Balance sheet well positioned to execute strategy Net bank debt at 31 Dec 2020 12.0 15.2 66.7 26.6 €74.0m Free cashflow (FCF %: 111%) (99.4) (7.9) (7.8) (39.8) (34.4) FCF impacted by timing FY 19 EBITDA Working 2 Non Rec Acquisition Capex Strategic Other 3 FY 20 differ

Slide 16: FCF Conversion and Normalised FCF
FCF Conversion Normalised FCF Medium-term Target Free Cashflow (FCF) 2020 2020 Adj €’m Reported Normalised 60% - 70% EBITDA 66.7 - 66.7 > We target FCF1 conversion of 60-70% Net Working 15.2 (26.0) (10.8) Capital > Normalised FCF of 72% after adjusting for timing differences, including: Capital (7.9

Slide 17: Liquidity and Planned Refinancing Completed
Liquidity Planned Refinancing Completed 31/12/2020 €’m ✓ 5-year agreement Cash & Cash equivalents1 63.5 ✓ Facility limits effectively doubled ✓ Improved interest rate Bank Borrowings (97.9) ✓ Term transitioned to revolver ✓ Multi-currency Net Bank Debt (34.4) New Previous Increase Facilities €’m €’m

Slide 18: Strategic Initiatives
Strategic Initiatives uniphar.ie 18

Slide 19: Divisional Objectives
Divisional Objectives Commercial Product Supply Chain & Clinical Access & Retail Pan-European Platform Market Leadership Market Share Client Growth Business Development Operational Optimisation Digital Solutions Patient Focused Symbol Group Leadership uniphar.ie 19

Slide 20: M&A: Continued Execution and Integration
M&A: Continued Execution and Integration Enhanced call-centre capability Commercial & Clinical Highly experienced management team Incl. HCPs and subject matter experts Digital Solutions Cross-divisional support service: US EAPs Outsourced product development expertise Product Access US regulatory kn

Slide 21: Commercial & Clinical: Scaling in Europe
Commercial & Clinical Scaling in Europe Currently Active 10% Near Term Organic growth opportunity European Platform Medium term target expansion M&A and Organic Strategy Deep expertise across key therapeutic areas delivering strong organic growth Organic market entry & evaluating potential bolt on a

Slide 22: Product Access: Global Capabilities
Product Access Global Capabilities 10% Market Leadership Strong Organic Growth of 29% 42% Integrated Uniphar / Durbin offering fuelling growth Increased scale & brand awareness driving continued opportunities RRD International clinical expertise strengthens US EAP capabilities Business Development S

Slide 23: Supply Chain & Retail: Market Leadership
Supply Chain & Retail Market Leadership 10% SC&R: Market Share Growth(1) Market Share Growth Trajectory; Market share >50% 2010 42% Domestic market leader in Supply Chain Supported by Higher margin retail offering 2020 0% 50% Operational Optimisation Leveraging our infrastructure Fragmented Retail M

Slide 24: Outlook & Investment Case
Outlook & Investment Case uniphar.ie 24

Slide 25: Medium term outlook unchanged & 2021 expected to deliver on plan
Medium term outlook unchanged & 2021 expected to deliver on plan Divisional Guidance | Medium term Group Guidance | Medium term metrics organic growth in gross profit: Product FCF ROCE Access Conversion Double Digit 12 - 15% 60% - 70% Commercial & Clinical Mid Single Digit Dividend Net Bank Debt / E

Slide 26: Investment Case
Investment Case Compelling Market Opportunity • Increasing requirements for speciality products • Continued growth in outsourcing Experienced by manufacturers Industry Team Experienced Compelling • Highly fragmented European • Executive management, line market management and specialty / Industry Mar

Slide 27: Q&A
Q&A 27

Slide 28: Contact Details
Uniphar.ie Contact Details Brian O’Shaughnessy Group Director of Corporate Development +353 (0)1 428 7777 investor.relations@Uniphar.ie Q4 PR Public Relations Adviser to Uniphar Iarla Mongey +353 (0)1 475 1444; or +353 (0)87 235 6461 28

Slide 29: Thank You
Uniphar.ie Thank You 29

Slide 30: Appendices
Appendices uniphar.ie 30

Slide 31: Uniphar History
Uniphar History Establishing our platform - 10 years of transformation Uniphar’s Heritage Design New Vision Build Differentiated Capabilities Internationalise and Scale 1967 2019 2019 United Pharmaceuticals 2010 IPO Acquisitions Co-Op Founded New senior management team appointed 1972 (led by Ger Rab

Slide 32: Peer Landscape
Peer Landscape Uniphar peers differ by division Supply Chain Commercial Product Access & Retail & Clinical Wholesale & Pharma Medical Device ‘On-demand’ Retail Business Exclusive Access (Pre-) Wholesale Services Services Access Global Peers Fragmented Independent Market uniphar.ie 32

Slide 33: Product Lifecycle Focus: Regulatory Approval
Product Lifecycle Focus Specific expertise across multiple geographies Development Clinical Pre-approval Pre-reimbursement Post-reimbursement Off Patent Stage Regulatory Approval Duration ~7 years < 1 Year < 2 years 10-15 years Longer of Stage • Global Product Access capability significantly enhance

Slide 34: Service Impact Case Studies
Commercial Product Access & Clinical Case Study Case Study » European headquartered biopharmaceutical company » Patient-focused, values-based, R&D-driven top 20 global biopharmaceutical company Client Client focused on treatments for CNS disorders » European rights for a new drug treating partial-on

Slide 35: Capital Allocation
Capital Allocation Reinvest to support growth Continue to invest in infrastructure, digital platforms, strategic Capex and talent to deliver organic growth in line with medium term guidance M&A Growing through M&A is a necessary component of delivering our 5 year plan ROCE hurdle rate of 12%-15% wit

Slide 36: Summary Management Balance Sheet
Summary Management Balance Sheet 1 Balance Sheet (€’000) 31 Dec 2020 31 Dec 2019 Goodwill 358,283 272,544 IFRS 16 Right of Use Asset 115,101 91,978 Other non-current assets 60,502 38,570 Total non-current assets 533,886 403,092 Inventory 115,566 97,684 Trade & other receivables 125,196 136,408 Asset

Slide 37: Return on Capital Employed
Return on Capital Employed (€’000) 2019 2020 Numerator Rolling 12 months operating profit 39,944 Adjustment for exceptional costs 6,775 Amortisation of acquisition related intangibles 279 Adjusted 12 months operating profit 46,998 Denominator1 Total equity 180,920 202,535 Net bank debt / (26,622) 34

Slide 38: Summary Group Financial Information
Summary Group Financial Information Year -ended 31 December €’000 Reported % 2020 2019 Growth Revenue 1,823,854 1,665,283 10% Gross profit 217,252 180,602 20% Overheads & operating income1 (150,539) (122,047) 23% EBITDA 66,713 58,555 14% Depreciation & amortisation (19,994) (18,305) 9% Exceptional i

Slide 39: EBITDA Reconciliation
EBITDA Reconciliation EBITDA is earnings before interest, tax, depreciation, amortisation and exceptional items. Year ended 31 December (€’000) 2020 2019 Operating profit pre exceptional 46,719 40,250 Depreciation 17,626 15,911 Amortisation 2,368 2,394 EBITDA 66,713 58,555 uniphar.ie 39
Source: Internet Archive copy of uniphar.ie
More decks from Uniphar PLC
H1 2026 Earnings Presentation39 slides · Sep 8, 2026
FY2025 Earnings Presentation39 slides · Feb 24, 2026
FY2024 Earnings Presentation38 slides · Feb 25, 2025
H1 2024 Earnings Presentation37 slides · Sep 3, 2024
FY2023 Earnings Presentation39 slides · Feb 27, 2024
H1 2023 Earnings Presentation41 slides · Sep 14, 2023